Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
Auditor change
Employment agrmnt
Oncotelic Therapeutics, Inc. (MATN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/23/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Sapu BioScience and Cromos Pharma initiating P201 – A Registrational trial for OT-101 in Pancreatic Cancer"
08/18/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/13/2023 D Form D - Notice of Exempt Offering of Securities:
07/13/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "SUBSCRIPTION AGREEMENT AND INVESTMENT LETTER",
"ONCOTELIC THERAPEUTICS, INC. COMMON STOCK PURCHASE WARRANT ________, 2023 THIS COMMON STOCK PURCHASE WARRANT of Oncotelic Therapeutics, Inc., a corporation duly organized and validly existing under the laws of Delaware , is issued to the Holder as part of a unit purchased by the Holder from the Company pursuant to which the Holder is also purchasing from the Company notes convertible into shares of its Common Stock, $0.01 par value per share warrants to purchase 250,000 Common Stock . FOR VALUE RECEIVED, the Company hereby certifies that the registered holder hereof, [●], with an address at [●], and the Holder’ s successors and assigns , is entitled to purchase from the Company [●] duly authorized, validly issued, fully paid and nonassessable shares of Common Stock, at a ...",
"Cover Page Interactive Data File (embedded within the Inline XBRL document)",
"REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement is made and entered into as of __________, 2023, by and among Oncotelic Therapeutics, Inc. , a Delaware corporation with offices at 29397 Agoura Road, Suite 107, Agoura Hills, California 91301, and the investors signatories hereto . This Agreement is made pursuant to the Subscription Agreement and Investment Letter, dated as of the date hereof, executed by each of the Purchasers and the Company . NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and the Purchasers agree as follows: 1. Definitio ns. Capitalized terms used and not otherwise defined herein that are defined in th..."
05/19/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "OF ONCOTELIC THERAPEUTICS, INC. a Delaware Corporation"
05/15/2023 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
05/02/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
04/26/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/14/2023 10-K Annual Report for the period ended December 31, 2022
03/13/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "High Intra-Tumor TGF-β2 Predicts Poor Survival in Pediatric Cancer of the Brainstem -The TGFβ1 and TGFβ3 isoforms are predictive —Validation of TGFβ2 as therapeutic target"
03/02/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/03/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "– JV continues to advance to its IPO - OT-101 immunotherapy expanding with at least 10 planned IIS clinical trials for 2023 - OT-101 commercialization effort expanding on multiple fronts - Manufacturing and DAO capabilities being built with platform launched slated for 2023 AGOURA HILLS, Calif., Dec. 28, 2022 – Oncotelic Therapeutics, Inc , a clinical stage cancer and aging biotechnology company, today issued a letter to its shareholders from its Chief Executive Officer, Dr. Vuong Trieu. To our Shareholders, 2022 was a defining year for Oncotelic as we entered into a JV agreement with Dragon Overseas Limited to form GMP Biosciences Limited to advance the development of OT-101 along multiple oncology indications through various pivotal internal studies and external investigator-initiated st..."
12/20/2022 8-K Quarterly results
11/18/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/14/2022 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
08/22/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/15/2022 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
07/15/2022 8-K Quarterly results
06/27/2022 8-K Quarterly results
06/22/2022 8-K Quarterly results
06/03/2022 8-K Quarterly results
05/23/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/16/2022 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
05/11/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/09/2022 EFFECT Form EFFECT - Notice of Effectiveness:
04/26/2022 POS AM Form POS AM - Post-Effective amendments for registration statement:
04/15/2022 10-K Annual Report for the period ended December 31, 2021
04/13/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Letter to Oncotelic Shareholders on the Recently Completed Joint Venture Transaction with Dragon Overseas Capital Limited AGOURA HILLS, Calif., April 7th , 2022 – Oncotelic Therapeutics, Inc. , issued the following shareholder letter today."
04/06/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Oncotelic and Dragon Overseas Capital Limited Completed Joint Venture Transaction"
04/04/2022 8-K Entered into an underwriting agreement for the issuance and sale of notes
04/01/2022 8-K Investor presentation
03/31/2022 NT 10-K Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405:
02/17/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
02/15/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy